Breaking News | GenomeWeb

Breaking News

Researchers hope to identify exosomal biomarkers that can predict or detect cancer recurrence and metastasis at its earliest stages.

The companies aim to offer integrated chemistry and biology services for ion channel drug discovery.

Dr Risch Medical Laboratory will distribute the firm's PCR-based colorectal cancer blood test in the Swiss German market and Lichtenstein.

The new fund aims to advance data-driven innovations by investing in academic research on and the commercialization of genomic and other technologies.

The firm said that the test may be validated as a prognostic test for colorectal cancer and a predictive test for cancer immunotherapies. 

The funding builds on more than $1.7 million already awarded to the firm, which is building a diagnostic for characterizing patients in clinical trials.

The company said the funds would be used to develop new products based on its proprietary mass spec technology.

The oncology assay is the first from Roche using either plasma or tumor tissue samples and identifies 42 mutations in the EGFR gene.

The company said it will use the proceeds to support the development of a prototype pathogen detection platform.

The company will provide DNA analysis services to a Norwegian salmon breeding consortium.

The firm will use MaxCyte's cell transfection platform to edit hematopoietic stem cells with CRISPR/Cas9 in hemoglobinopathy and SCID.

Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.

The firms extended their OVA1 commercialization agreement an additional year while adding procedures for verifying the number of tests performed under the deal.

Catalyst will use Biocept's liquid biopsy platform to screen for cancer in patients in a clinical study of its rare disease drug Firdapse.

Revenues from the company's clinical labs segment grew 8 percent this quarter, and revenues from the life sciences business grew 6 percent.

Researchers sequenced the mitochondrial genomes of two ancient bison and compared them to other bison samples, and found two waves of bison dispersal.

An integrated analysis of uterine carcinosarcomas uncovered a range of somatic mutations and shifts in transcription, methylation, and microRNA expression.

Using a new mathematical model, researchers uncovered mutational signatures related to homologous recombination deficiency in up to one-fifth of breast cancers.

The consortium will analyze genotypic and phenotypic data from the Qatar Biobank, with the goal of developing individualized disease treatments and prevention methods.

Last week, GenomeWeb's readers were most interested in two new papers that characterized the mutational landscape of autism spectrum disorder.

The researchers also reported, however, that patient-derived xenografts could help identify possible treatment approaches.

An NHGRI-led team found a variant in the SEMA4D gene that was present in people of African descent, but not in people of Asian or European ancestry.

The companies have expanded their relationship to include the development and automation of assays for clinical trials and clinical testing.

MethylCap-seq data for dozens of primary endometrioid endometrial cancers led to a 13-region methylation signature linked to broader tumor genome features.

Pages

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.